MaxCyte (NASDAQ:MXCT) has signed a non-exclusive licensing deal with Vertex Pharmaceuticals (NASDAQ:VRTX) allowing the latter to use MaxCyte's (MXCT) Flow Electroporation technology and ExPERT™ platform to develop gene-edited therapy exa-cel, previously known as CTX001.
Exact financial terms were not disclosed.
Exa-cel is an investigational ex vivo CRISPR/Cas-9 gene-edited cell therapy under investigation for transfusion-dependent beta thalassemia or sickle cell disease.
MaxCyte's (MXCT) technology was also used in an agreement between the company and CRISPR Therapeutics (CRSP). Vertex is developing exa-cel, currently in phase 2/3, with CRISPR (CRSP).